Company Pear Therapeutics, Inc.

Equities

PEARQ

US7047231052

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 07:33:36 22/03/2024 pm IST			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-.--%

22/03	Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc.	CI
04/03	Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc.	CI

Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Companyâs pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.

Number of employees: 200

USD in Million	2021	Weight	2022	Weight	Delta
Prescription Digital Therapeutics 82.1 %	4	89.1 %	10	82.1 %	+177.93%
Subscription, Support, and Professional Services 11.1 %	-	-	1	11.1 %	-
Collaboration and License 6.9 %	0	10.9 %	1	6.9 %	+89.57%

USD in Million	2021	Weight	2022	Weight	Delta
United States 100.0 %	4	100.0 %	13	100.0 %	+201.66%

Managers	Title	Age	Since
Christopher Guiffre CEO	Chief Executive Officer	56	-
Maria Sullivan CTO	Chief Tech/Sci/R&D Officer	-	-
Yuri Maricich CTO	Chief Tech/Sci/R&D Officer	44	-
Ilya Gluhovsky CTO	Chief Tech/Sci/R&D Officer	-	-
Corey McCann BRD	Director/Board Member	45	01/21/01
Meara Murphy IRC	Investor Relations Contact	-	-
Beth Keyt LAW	General Counsel	-	-
Chris Valosky SAM	Sales & Marketing	-	-
Ellen Snow AUD	Comptroller/Controller/Auditor	-	-
Anthony L. Watson LAW	General Counsel	82	-

Members of the board	Title	Age	Since
Nancy Schlichting BRD	Director/Board Member	69	01/21/01
Timothy A. Wicks BRD	Director/Board Member	58	14/22/14
Corey McCann BRD	Director/Board Member	45	01/21/01
Alison Bauerlein BRD	Director/Board Member	42	01/21/01
Shiva Rajaraman BRD	Director/Board Member	50	14/22/14
Paul Mango BRD	Director/Board Member	-	14/22/14

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	142,739,169	125,471,827 ( 87.90 %)	0	87.90 %

Name	Equities	%	Valuation
Corey McCann 7.625 %	10,883,264	7.625 %	- $
LJ10 LLC 4.475 %	6,387,026	4.475 %	- $
Yuri Maricich 0.0661 %	94,333	0.0661 %	- $
Alison Bauerlein 0.0500 %	71,428	0.0500 %	- $
Nancy Schlichting 0.0467 %	66,666	0.0467 %	- $
Kirthiga Reddy 0.0434 %	61,904	0.0434 %	- $
Shiva Rajaraman 0.0367 %	52,380	0.0367 %	- $
Timothy A. Wicks 0.0367 %	52,380	0.0367 %	- $
Paul Mango 0.0367 %	52,380	0.0367 %	- $
Erin K. Brenner 0.0303 %	43,310	0.0303 %	- $

Name	Equities	%	Valuation
Telemetry Investments LLC -	85,742	-	86 $

Pear Therapeutics, Inc.

200 State Street 13th Floor

02109, Boston

http://www.peartherapeutics.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
PEAR THERAPEUTICS, INC.	-.--%	142
MODERNA, INC.	+22.56%	46.71B
IQVIA HOLDINGS INC.	-1.51%	41.52B
LONZA GROUP AG	+48.83%	41.8B
CELLTRION, INC.	-3.42%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.13%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.44%	19.26B
MEDPACE HOLDINGS, INC.	+26.45%	11.98B
BIO-TECHNE CORPORATION	-0.14%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.47%	12.08B

Other Biotechnology & Medical Research